| Latest LA Jolla Pharmaceutical News Headlines |
| Date | Time | Source | |
| 02/13/2009 | 9:00AM | PRNUS | Beacon Equity Issues Trade Alerts on Market Movers: ECL, PTEN, LJPC, KO, KSS, TDC
DALLAS, Feb. 13 /PRNewswire/ -- BeaconEquity.com announces the availability of Trade Alerts on stocks making news today.
Investors can view all of the daily trading notes for free by visiting:
http://www.beaconequity.com/m
Today's Trade Alerts include: Ecolab Inc. (NYSE:ECL), Patterson-UTI Energy Inc. (NASDAQ:PTEN... More...>> |
| 01/06/2009 | 4:30PM | PRNUS | BioMarin and La Jolla Pharmaceutical Sign Worldwide (Excluding Asia Pacific) Development and Commercialization Agreement for Riq
Riquent is Currently Being Evaluated in a Phase 3 Clinical Study for Lupus Nephritis, A High Unmet Need and Orphan Disease
NOVATO, Calif. and SAN DIEGO, Jan. 6 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) and La Jolla Pharmaceutical Company (NASDAQ:LJPC) announced today that they have entered... More...>> |
| 06/07/2007 | 7:30AM | PRNUS | La Jolla Pharmaceutical Company to Present at Needham Healthcare Conference
SAN DIEGO, June 7 /PRNewswire-FirstCall/ -- La Jolla Pharmaceutical Company (NASDAQ:LJPC) today announced that Deirdre Y. Gillespie, M.D., President and Chief Executive Officer, will present on Wednesday, June 13 at 2:30 pm Eastern Time during the Needham Healthcare Conference. The conference will take place at The... More...>> |
| 05/24/2007 | 7:30AM | PRNUS | La Jolla Pharmaceutical Company Reports Riquent(R) Well Tolerated in Three Studies at International Lupus Congress
SAN DIEGO, May 24 /PRNewswire-FirstCall/ -- La Jolla Pharmaceutical Company (NASDAQ:LJPC) today announced that it presented three papers related to Riquent(R) (abetimus sodium), its drug candidate for systemic lupus erythematosus ("lupus" or "SLE") at the 8th International Congress on SLE. The first presentation reviewed... More...>> |
| 05/10/2007 | 5:10PM | PRNUS | La Jolla Pharmaceutical Company Names Niv Caviar Chief Business and Financial Officer
SAN DIEGO, May 10 /PRNewswire-FirstCall/ -- La Jolla Pharmaceutical Company (NASDAQ:LJPC) today announced that Niv E. Caviar has joined the Company as Executive Vice President, Chief Business Officer and Chief Financial Officer.
Mr. Caviar was most recently Vice President and Head of Marketing at Allergan, an $18 billion... More...>> |
| 05/03/2007 | 7:30AM | PRNUS | La Jolla Pharmaceutical Company Reports First Quarter Financial Results
SAN DIEGO, May 3 /PRNewswire-FirstCall/ -- La Jolla Pharmaceutical Company (NASDAQ:LJPC) reported a net loss for the first quarter ended March 31, 2007 of $11.9 million, or $0.36 per share (on 32.7 million weighted-average shares), compared to a net loss of $10.9 million, or $0.33 per share (on 32.5 million weighted-average... More...>> |
| 04/26/2007 | 7:30AM | PRNUS | La Jolla Pharmaceutical Receives Riquent(R) Composition of Matter Patents in Europe and China
SAN DIEGO, April 26 /PRNewswire-FirstCall/ -- La Jolla Pharmaceutical Company (NASDAQ:LJPC) today announced that composition of matter patents covering Riquent(R) (abetimus sodium), its drug candidate for systemic lupus erythematosus ("lupus" or "SLE") have issued in both Europe and in the People's Republic of China... More...>> |
| 04/26/2007 | 7:30AM | PRNUS | La Jolla Pharmaceutical Receives Riquent(R) Composition of Matter Patents in Europe and China
SAN DIEGO, April 26 /PRNewswire-FirstCall/ -- La Jolla Pharmaceutical Company (NASDAQ:LJPC) today announced that composition of matter patents covering Riquent(R) (abetimus sodium), its drug candidate for systemic lupus erythematosus ("lupus" or "SLE") have issued in both Europe and in the People's Republic of China... More...>> |
| 04/10/2007 | 4:44PM | PRNUS | La Jolla Pharmaceutical Company Announces Exercise of Full Over-Allotment Option
SAN DIEGO, April 10 /PRNewswire-FirstCall/ -- La Jolla Pharmaceutical Company (NASDAQ:LJPC) today announced that the underwriters of the Company's recently completed public offering have exercised in full their over-allotment option to purchase an additional 870,000 shares of common stock from the Company at the initial... More...>> |
| 03/29/2007 | 10:24PM | PRNUS | La Jolla Pharmaceutical Company Announces Pricing of Common Stock Offering
SAN DIEGO, March 29 /PRNewswire-FirstCall/ -- La Jolla Pharmaceutical Company (NASDAQ:LJPC) today announced the pricing of an underwritten public offering of 5,800,000 shares of its common stock at $6.00 per share for a total offering of $34.8 million. All of the shares are being sold by the Company. The offering... More...>> |
| 03/20/2007 | 8:30AM | PRNUS | La Jolla Pharmaceutical Company Announces Proposed Public Offering of Common Stock
SAN DIEGO, March 20 /PRNewswire-FirstCall/ -- La Jolla Pharmaceutical Company (NASDAQ:LJPC) today announced plans to offer 5,000,000 shares of common stock in an underwritten public offering pursuant to an effective shelf registration statement. The Company intends to grant the underwriters an option to purchase an... More...>> |
| 03/20/2007 | 8:30AM | PRNUS | La Jolla Pharmaceutical Provides Update on Interim Antibody Results From Riquent(R) Lupus Phase 3 Trial
SAN DIEGO, March 20 /PRNewswire-FirstCall/ -- La Jolla Pharmaceutical Company (NASDAQ:LJPC) today announced updated interim antibody reduction data for the Phase 3 trial of Riquent(R) (abetimus sodium), its drug candidate for systemic lupus erythematosus ("lupus" or "SLE"). The updated analyses reinforce the previous... More...>> |
| 03/08/2007 | 7:00AM | PRNUS | La Jolla Pharmaceutical Announces Positive Interim Antibody Results From Riquent(R) Lupus Phase 3 Trial
Data Support Ability of Higher Doses to Further Reduce Antibodies to Double-Stranded DNA
SAN DIEGO, March 8 /PRNewswire-FirstCall/ -- La Jolla Pharmaceutical Company (NASDAQ:LJPC) today announced positive interim antibody results from its ongoing double-blind, placebo-controlled randomized Phase 3 trial of Riquent(R... More...>> |
| 03/01/2007 | 7:30AM | PRNUS | La Jolla Pharmaceutical Company Reports Fourth Quarter and Year-to-Date Financial Results
SAN DIEGO, March 1 /PRNewswire-FirstCall/ -- La Jolla Pharmaceutical Company (NASDAQ:LJPC) reported a net loss for the fourth quarter ended December 31, 2006 of $10.7 million, or $0.33 per share (on 32.7 million weighted average shares), compared to a net loss of $6.0 million, or $0.33 per share (on 18.3 million weighted... More...>> |
| 02/08/2007 | 7:30AM | PRNUS | La Jolla Pharmaceutical Company to Present at BIO CEO & Investor Conference
SAN DIEGO, Feb. 8 /PRNewswire-FirstCall/ -- La Jolla Pharmaceutical Company (NASDAQ:LJPC) today announced that Deirdre Y. Gillespie, M.D., President and Chief Executive Officer of La Jolla Pharmaceutical Company, will present on Tuesday, February 13th at 4:30 p.m. Eastern Time during the BIO CEO & Investor Conference... More...>> |
| 02/08/2007 | 7:30AM | PRNUS | La Jolla Pharmaceutical Company to Present at BIO CEO & Investor Conference
SAN DIEGO, Feb. 8 /PRNewswire-FirstCall/ -- La Jolla Pharmaceutical Company (NASDAQ:LJPC) today announced that Deirdre Y. Gillespie, M.D., President and Chief Executive Officer of La Jolla Pharmaceutical Company, will present on Tuesday, February 13th at 4:30 p.m. Eastern Time during the BIO CEO & Investor Conference... More...>> |
| 02/01/2007 | 7:30AM | PRNUS | La Jolla Pharmaceutical Announces Continued Enrollment Progress and Enhancements to International Phase 3 Riquent(R) Study
SAN DIEGO, Feb. 1 /PRNewswire-FirstCall/ -- La Jolla Pharmaceutical Company (NASDAQ:LJPC) today announced its continued progress in enrolling patients in its Phase 3 clinical trial of Riquent(R) (abetimus sodium) for the treatment of lupus renal disease. In addition, following recent discussions with the Food and Drug... More...>> |
| 11/06/2006 | 7:30AM | PRNUS | La Jolla Pharmaceutical Announces Continued Progress With Phase 3 International Riquent(R) Study
SAN DIEGO, Nov. 6 /PRNewswire-FirstCall/ -- La Jolla Pharmaceutical Company (NASDAQ:LJPC) today announced significant progress in enrolling patients and opening sites for its Phase 3 clinical trial of Riquent(R) (abetimus sodium) for the treatment of lupus renal disease. To date, 82 patients have been enrolled in the... More...>> |
| 11/02/2006 | 7:30AM | PRNUS | La Jolla Pharmaceutical Company Reports Third Quarter and Year-to-Date Financial Results
SAN DIEGO, Nov. 2 /PRNewswire-FirstCall/ -- La Jolla Pharmaceutical Company (NASDAQ:LJPC) reported a net loss for the third quarter ended September 30, 2006 of $8.5 million, or $0.26 per share (on 32.5 million weighted average shares), compared to a net loss of $5.9 million, or $0.40 per share (on 14.8 million weighted... More...>> |
| 11/01/2006 | 7:30AM | PRNUS | La Jolla Pharmaceutical Company to Present at Rodman & Renshaw 8th Annual Healthcare Conference
SAN DIEGO, Nov. 1 /PRNewswire-FirstCall/ -- La Jolla Pharmaceutical Company (NASDAQ:LJPC) today announced that Deirdre Y. Gillespie, M.D., President and Chief Executive Officer of La Jolla Pharmaceutical Company, will present at the Rodman & Renshaw 8th Annual Healthcare Conference on Monday, November 6, 2006 at 10:35... More...>> |